At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
|Articles|May 14, 2012
Michael Einodshofer, RPh, MBA, Discusses Site of Care Optimization Programs
Michael Einodshofer, RPh, MBA, points out the benefits to members from Site of Care Optimization programs.
Advertisement
Michael Einodshofer, RPh, MBA, Director of Utilization Management, Walgreens Specialty Pharmacy, addresses Site of Care Optimization as a strategy for health plans to lower costs on specialty drugs. Mr. Einodshofer also states that Site of Care Optimization improves member satisfaction and adherence.
Advertisement
Related to this article
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
3
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
4
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
5